# Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies

**Authors:** Sonja Fernbach, Nina K. Mair, Irene A. Abela, Kevin Groen, Roger Kuratli, Marie Lork, Christian W. Thorball, Enos Bernasconi, Paraskevas Filippidis, Karoline Leuzinger, Julia Notter, Andri Rauch, Hans H. Hirsch, Michael Huber, Huldrych F. Günthard, Jacques Fellay, Roger D. Kouyos, Benjamin G. Hale, Irene A. Abela, Irene A. Abela, Karoline Aebi-Popp, Alexia Anagnostopoulos, Manuel Battegay, Enos Bernasconi, Dominique Laurent Braun, Heiner Bucher, Alexandra Calmy, Matthias Cavassini, Angela Ciuffi, Günter Dollenmaier, Matthias Egger, Luisa Elzi, Jan Fehr, Jacques Fellay, Hansjakob Furrer, Christoph Fux, Huldrych Fritz Günthard, Anna Hachfeld, David Haerry, Barbara Hasse, Hans Hirsch, Matthias Hoffmann, Irene Hösli, Michael Huber, David Jackson-Perry, Christian Kahlert, Laurent Kaiser, Olivia Keiser, Thomas Klimkait, Roger Dimitri Kouyos, Helen Kovari, Katharina Kusejko, Niklaus Labhardt, Karoline Leuzinger, Begogna Martinez de Tejada, Catja Marzolini, Karin Jutta Metzner, Nicolas Müller, Johannes Nemeth, Dunja Nicca, Julia Notter, Paolo Paioni, Giuseppe Pantaleo, Matthieu Perreau, Andri Rauch, Luisa Salazar-Vizcaya, Patrick Schmid, Roberto Speck, Marcel Stöckle, Philip Tarr, Alexandra Trkola, Gilles Wandeler, Maja Weisser, Sabine Yerly

PMC · DOI: 10.1084/jem.20240365 · 2024-07-17

## TL;DR

This study shows that the loss of immune tolerance to type I interferons occurs before autoantibody development and leads to lifelong susceptibility to infections.

## Contribution

The study reveals that age-related loss of self-tolerance precedes anti-IFN-I autoantibody development and increases infection risk.

## Key findings

- Anti-IFN-I autoantibodies persist lifelong and increase in titer over decades.
- Neutralizing anti-IFNα autoantibodies correlate with reduced IFN-stimulated gene levels and severe COVID-19.
- Pre-existing autoreactivity and prior viral infections are linked to anti-IFN-I autoantibody emergence.

## Abstract

Rare autoantibodies neutralizing type I IFNs can underlie viral disease severity. Here, the authors dissect immunological and age-related factors associated with anti-IFN-I autoantibody development in individuals over a 35-year period and further reveal the lifelong infection susceptibility that results.

Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% of individuals acquired anti-IFN-I autoantibodies as they aged (median onset ∼63 years). Once detected, anti-IFN-I autoantibodies persisted lifelong, and titers increased over decades. Individuals developed distinct neutralizing and non-neutralizing autoantibody repertoires at discrete times that selectively targeted combinations of IFNα, IFNβ, and IFNω. Emergence of neutralizing anti-IFNα autoantibodies correlated with reduced baseline IFN-stimulated gene levels and was associated with subsequent susceptibility to severe COVID-19 several years later. Retrospective measurements revealed enrichment of pre-existing autoreactivity against other autoantigens in individuals who later developed anti-IFN-I autoantibodies, and there was evidence for prior viral infections or increased IFN at the time of anti-IFN-I autoantibody triggering. These analyses suggest that age-related loss of self-tolerance prior to IFN-I immune-triggering poses a risk of developing lifelong functional IFN-I deficiency.

## Linked entities

- **Proteins:** IFN1@ (interferon, type 1, cluster), IFNB1 (interferon beta 1)

## Full-text entities

- **Genes:** IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}
- **Diseases:** IFN-I deficiency (MESH:D006969), COVID-19 (MESH:D000086382), viral infections (MESH:D014777), infection (MESH:D007239), HIV (MESH:D015658)

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11253716/full.md

---
Source: https://tomesphere.com/paper/PMC11253716